BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung CancerGlobeNewsWire · 4 days ago
BlossomHill Therapeutics (NASDAQ:BLSM) Shares Down 4.9% – Time to Sell?Defense World · Oct 2, 2026
BlossomHill Therapeutics (NASDAQ:BLSM) Shares Gap Up – Here’s WhyDefense World · Oct 1, 2026
BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic CancerGlobeNewsWire · Sep 28, 2026
BlossomHill Therapeutics Reports Second Quarter 2026 Financial ResultsGlobeNewsWire · Sep 18, 2026
BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung CancerGlobeNewsWire · Sep 15, 2026Blossomhill Therapeutics, Inc. is a biopharmaceutical company. It engages in the development of small molecule medicines for unmet medical needs in cancer treatment. The company was founded in June 2020 and is headquartered in San Diego, CA.